TRV
Another analyst joins the Travelers fan club
BMO Capital Markets just nudged its price target on Travelers Companies up to $314 from $297 and kept the stock at Outperform. Translation: the analyst crowd still thinks the insurer has room to run, even after a pretty spicy first quarter.
Why this matters
Travelers is already trading around $303.89, which is basically making itself comfortable near its 52-week high of $313.12. So this isn’t some “suddenly discovered the company exists” kind of note — it’s more like Wall Street saying, “Yep, the numbers still look good, and we’re not done yet.”
The earnings hangover? Not much of one
The note comes on the heels of Travelers’ Q1 2026 results, where the company beat on both earnings and revenue. In analyst-land, that tends to trigger a small parade of price-target tweaks, and Travelers is getting the full treatment:
- Evercore ISI lifted its target too, to $321
- BofA Securities went in the opposite direction on rating but still moved its target around
- BMO is sticking with the bullish camp
So if you own TRV, the message is pretty simple: the Street likes the underwriting story, likes the earnings momentum, and doesn’t seem in a hurry to fade the stock.
Big picture
When insurers can beat expectations and still get fresh target hikes, that’s usually a sign the market thinks the business has a little extra juice left. Not exactly Super Bowl-level drama, but for a boring-old insurance name? Pretty solid.